L-type amino acid transporter 1 (LAT1) and LAT2 were shown to encode system L, which mediates the Na +-independent transport of branched-chain and aromatic amino acids. We demonstrated previously that LAT2 is a progesterone receptor target gene involved in leiomyoma growth. The role of LAT1 in the regulation of human uterine leiomyoma growth, however, remains unelucidated. We herein investigated the function of LAT1 and its progesterone-mediated regulation within human uterine leiomyoma smooth muscle (LSM) cells (n = 8) and tissues (n = 29). In vivo, LAT1 expression was higher in leiomyoma than in myometrial tissue. LAT1 knockdown augmented cell proliferation and viability. Treatment of LSM cells with RU486 markedly increased LAT1 messenger RNA (mRNA) levels but decreased proliferation in a dose-dependent manner. L-type amino acid transporter 1 as a downstream target, however, did not entirely account for this antiproliferative effect of RU486 on LSM cells. Taken together, LAT1 may have a critical and complex role in regulating human leiomyoma cell growth.
Vollenhoven BJ, Lawrence AS, Healy DLUterine fibroids: a clinical review. Br J Obstet Gynaecol. 1990;97(4):285-298.
2.
Moller C., Hoffmann J., Kirkland TA, Schwede W.Investigational developments for the treatment of progesterone-dependent diseases . Expert Opin Investig Drugs. 2008;17(4):469-479.
3.
Kurachi O., Matsuo H., Samoto T., Maruo T.Tumor necrosis factor-alpha expression in human uterine leiomyoma and its down-regulation by progesterone. J Clin Endocrinol Metab. 2001;86(5):2275-2280.
4.
Maruo T., Ohara N., Wang J., Matsuo H.Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum Reprod Update. 2004;10(3):207-220.
5.
Matsuo H., Maruo T., Samoto T.Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J Clin Endocrinol Metab. 1997;82(1):293-299.
6.
Shimomura Y. , Matsuo H., Samoto T., Maruo T.Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma. J Clin Endocrinol Metab. 1998;83(6):2192-2198.
7.
Yin P., Lin Z., Cheng YH, et al. Progesterone receptor regulates Bcl-2 gene expression through direct binding to its promoter region in uterine leiomyoma cells. J Clin Endocrinol Metab. 2007;92(11):4459-4466.
8.
Yin P., Lin Z., Reierstad S., et al. Krüppel-like transcription factor 11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells. Cancer Res.2010;70(4): 1722-1730.
9.
Luo X., Yin P., Reierstad S., et al. Progesterone and mifepristone regulate L-type amino acid transporter 2 and 4F2 heavy chain expression in uterine leiomyoma cells. J Clin Endocrinol Metab.2009;94(11):4533-4539.
10.
Kaira K., Oriuchi N., Imai H., et al. L-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. Cancer Sci. 2008;99(12):2380-2386.
11.
Kim CH, Park KJ, Park JR, et al. The RNA interference of amino acid transporter LAT1 inhibits the growth of KB human oral cancer cells. Anticancer Res. 2006;26(4B):2943-2948.
Yanagida O., Kanai Y., Chairoungdua A., et al. Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta. 2001;1514(2):291-302.
14.
Rossi MJ, Chegini N., Masterson BJPresence of epidermal growth factor, platelet-derived growth factor, and their receptors in human myometrial tissue and smooth muscle cells: their action in smooth muscle cells in vitro. Endocrinology. 1992;130(3): 1716-1727.
15.
Kim DK, Kanai Y., Choi HW, et al. Characterization of the system L amino acid transporter in T24 human bladder carcinoma cells. Biochim Biophys Acta. 2002;1565(1):112-121.
16.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402-408.
17.
Steinauer J. , Pritts EA, Jackson R., Jacoby AFSystematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol. 2004;103(6):1331-1336.
18.
Kanai Y., Segawa H., Miyamoto K., Uchino H., Takeda E., Endou H.Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem. 1998;273(37):23629-23632.
19.
Kim DK, Kim IJ, Hwang S., et al. System L-amino acid transporters are differently expressed in rat astrocyte and C6 glioma cells. Neurosci Res. 2004;50(4):437-446.
20.
Shennan DB, Thomson J., Gow IF, Travers MT, Barber MCLleucine transport in human breast cancer cells (MCF-7 and MDA-MB-231): kinetics, regulation by estrogen and molecular identity of the transporter. Biochim Biophys Acta. 2004;1664(2):206-216.
21.
Yoon JH, Kim IJ, Kim H., et al. Amino acid transport system L is differently expressed in human normal oral keratinocytes and human oral cancer cells. Cancer Lett. 2005;222(2):237-245.
22.
Meier C., Ristic Z., Klauser S., Verrey F.Activation of system L heterodimeric amino acid exchangers by intracellular substrates. EMBO J. 2002;21(4):580-589.
23.
Graham JD, Clarke CLPhysiological action of progesterone in target tissues. Endocr Rev. 1997;18(4):502-519.
24.
Jacobsen BM , Richer JK, Schittone SA, Horwitz KBNew human breast cancer cells to study progesterone receptor isoform ratio effects and ligand-independent gene regulation. J Biol Chem. 2002;277(31):27793-27800.
25.
Leo JC, Lin VCThe activities of progesterone receptor isoform A and B are differentially modulated by their ligands in a gene-selective manner. Int J Cancer. 2008;122(1):230-243.
26.
Busso N., Collart M., Vassalli JD, Belin D.Antagonist effect of RU 486 on transcription of glucocorticoid-regulated genes . Exp Cell Res. 1987;173(2):425-430.
27.
Gagne D., Pons M., Crastes de Paulet A.Analysis of the relation between receptor binding affinity and antagonist efficacy of anti-glucocorticoids. J Steroid Biochem. 1986;25(3):315-322.
28.
Neef G., Beier S., Elger W., Henderson D., Wiechert R.New steroids with antiprogestational and antiglucocorticoid activities. Steroids. 1984;44(4):349-372.
